Unavailable
Unavailable
Save time and jump to the most important pieces.
Company Now Trading Under Ticker Symbol "NVNO"IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully completed its rebranding and that its shares are now trading under the ticker symbol "NVNO" on The Nasdaq Capital Market. The Company was formerly called Hancock Jaffe Laboratories, Inc.For shareholders of the Company holding shares in electronic form, the name change will require no action. Shareholders with physical stock certificates should contact the Company's transfer agent to obtain new certificates.For more i
Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe LaboratoriesIRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, today announced that Robert Berman, CEO of Hancock Jaffe will participate in The Duologue Series hosted by Ladenburg Thalmann on Monday, September 27, 2021 at 1:00 PM ET.The webinar will be moderated by Jeffrey S. Cohen, Managing Director of Ladenburg Thalmann. Following the discussion, there will be a question and answer se
- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -- Development strategy to focus on venous disease and advancement of the VenoValve® -- Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 -- Management to host a conference call with live video webcast at 4:30 p.m. ET today, September 21st -IRVINE, CA / ACCESSWIRE / September 21, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, announced today a corporate update which
SC 13G - Hancock Jaffe Laboratories, Inc. (0001661053) (Subject)
SC 13G - Hancock Jaffe Laboratories, Inc. (0001661053) (Subject)
8-K - enVVeno Medical Corp (0001661053) (Filer)
8-K - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)
8-K - Hancock Jaffe Laboratories, Inc. (0001661053) (Filer)
4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)
4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)
4 - Hancock Jaffe Laboratories, Inc. (0001661053) (Issuer)
- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -- Development strategy to focus on venous disease and advancement of the VenoValve® -- Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 -- Management to host a conference call with live video webcast at 4:30 p.m. ET today, September 21st -IRVINE, CA / ACCESSWIRE / September 21, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, announced today a corporate update which
Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ETIRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Hancock Jaffe management will host a corporate update conference call with a live video webcast on Tuesday, September 21, 2021 at 4:30 p.m. ET.As part of the call, management will discuss VenoValve's continued development and other ongoing corporate initiatives. The call will be led by Robert Berman, Chief Executive Officer of Hancock Jaffe, who will be joined by Dr. Marc Glickman